Karyopharm Therapeutics (NASDAQ:KPTI) Releases Quarterly Earnings Results, Beats Estimates By $0.21 EPS

Karyopharm Therapeutics (NASDAQ:KPTI) announced its quarterly earnings data on Thursday. The company reported ($1.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.45) by $0.21, FiscalAI reports. The firm had revenue of $35.07 million for the quarter, compared to analysts’ expectations of $31.40 million.

Here are the key takeaways from Karyopharm Therapeutics’ conference call:

• Karyopharm said its phase III SENTRY trial in myelofibrosis met the main spleen response endpoint, with SVR35 at week 24 of 50% versus 28% for ruxolitinib alone and no new safety signals.
• The company highlighted an encouraging overall survival signal in SENTRY, along with early variant allele frequency reductions that it believes may suggest disease-modifying activity.
• XPORT-EC-042 in endometrial cancer has completed enrollment, and Karyopharm still expects top-line data in mid-2026 for the biomarker-driven maintenance study.
• Management argued that its endometrial cancer program targets a large subgroup of TP53 wild-type, MMR-proficient patients and emphasized that the 60 mg weekly selinexor dose with mandated antiemetics should improve tolerability versus earlier studies.
• First-quarter revenue rose to $35.1 million from $30.0 million a year ago, but management said underlying XPOVIO demand fell versus last year due to new competition; it reaffirmed full-year 2026 revenue and expense guidance and said liquidity should last into late Q3 2026.

Karyopharm Therapeutics Price Performance

NASDAQ KPTI traded up $0.19 during trading hours on Thursday, hitting $9.04. The company had a trading volume of 714,999 shares, compared to its average volume of 815,456. Karyopharm Therapeutics has a fifty-two week low of $3.65 and a fifty-two week high of $10.99. The company has a market capitalization of $203.86 million, a price-to-earnings ratio of -0.54 and a beta of 0.80. The firm’s 50 day moving average is $7.91 and its 200 day moving average is $7.24.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Rodman & Renshaw upgraded Karyopharm Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 10th. Cantor Fitzgerald assumed coverage on Karyopharm Therapeutics in a research report on Thursday, February 5th. They set an “overweight” rating on the stock. Robert W. Baird reduced their target price on Karyopharm Therapeutics from $21.00 to $15.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 25th. HC Wainwright increased their price target on shares of Karyopharm Therapeutics from $8.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $16.00 price target (up from $8.00) on shares of Karyopharm Therapeutics in a research note on Monday, April 27th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $17.17.

Institutional Trading of Karyopharm Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Baird Financial Group Inc. acquired a new position in Karyopharm Therapeutics during the 2nd quarter worth approximately $45,000. XTX Topco Ltd acquired a new position in Karyopharm Therapeutics during the 2nd quarter worth approximately $56,000. Corient Private Wealth LLC acquired a new position in Karyopharm Therapeutics during the 4th quarter worth approximately $74,000. Tudor Investment Corp ET AL acquired a new position in Karyopharm Therapeutics during the 4th quarter worth approximately $95,000. Finally, Persistent Asset Partners Ltd acquired a new position in Karyopharm Therapeutics during the 4th quarter worth approximately $135,000. 66.44% of the stock is currently owned by institutional investors and hedge funds.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.